Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

85
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
85
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

601
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
601
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

620
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
620
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

367
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
367
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

146
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
146

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Idarucizumab.

Hospital pharmacy·2024
Same author

Fentanyl Iontophoretic Transdermal System.

Hospital pharmacy·2024
Same author

Fifty Years of Publication: Hospital Pharmacy Anniversary.

Hospital pharmacy·2024
Same author

Rolapitant.

Hospital pharmacy·2024
Same author

Zafirlukast: Chronic Urticaria.

Hospital pharmacy·2016
Same author

Elbasvir/Grazoprevir.

Hospital pharmacy·2016

Related Experiment Video

Updated: Jun 26, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K

Fosinopril: HIV-Associated Nephropathy (HIVAN).

Joyce A Generali1, Dennis J Cada2

  • 1Hospital Pharmacy, and Emeritus, Department of Pharmacy Practice, University of Kansas, School of Pharmacy, Kansas City/Lawrence, Kansas.

Hospital Pharmacy
|May 15, 2024
PubMed
Summary

This resource helps healthcare professionals quickly find and evaluate off-label drug uses. It guides clinicians in determining the rationality of unapproved drug applications in patient care scenarios.

More Related Videos

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

10.2K
Cellular Redox Profiling Using High-content Microscopy
11:37

Cellular Redox Profiling Using High-content Microscopy

Published on: May 14, 2017

10.9K

Related Experiment Videos

Last Updated: Jun 26, 2025

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

17.8K
Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty
07:27

Exergaming in Older People Living with HIV Improves Balance, Mobility and Ameliorates Some Aspects of Frailty

Published on: October 6, 2016

10.2K
Cellular Redox Profiling Using High-content Microscopy
11:37

Cellular Redox Profiling Using High-content Microscopy

Published on: May 14, 2017

10.9K

Area of Science:

  • Pharmacy Practice
  • Clinical Pharmacology
  • Drug Information

Background:

  • Off-label drug use refers to prescribing medications for conditions not approved by regulatory bodies like the US Food and Drug Administration (FDA).
  • Practitioners require reliable resources to navigate the complexities of unapproved drug indications.
  • Existing literature may be fragmented, making it challenging to assess the evidence for off-label drug applications.

Purpose of the Study:

  • To provide a practitioner-oriented resource for information on off-label drug uses.
  • To enable healthcare professionals to efficiently identify published studies on unapproved drug indications.
  • To assist clinicians in determining the rationality of specific off-label drug uses in patient care.

Main Methods:

  • Extraction of relevant information from the publication 'Off-Label Drug Facts'.
  • Compilation of a guide to the scientific literature concerning off-label drug applications.
  • Organization of references to direct users to comprehensive literature for informed decision-making.

Main Results:

  • A structured guide is presented for accessing and evaluating off-label drug information.
  • The resource facilitates the identification of published studies supporting or refuting off-label drug uses.
  • Clinicians can utilize this guide to assess the evidence base for specific unapproved drug indications.

Conclusions:

  • 'Off-Label Drug Facts' serves as a valuable tool for healthcare professionals managing unapproved drug uses.
  • The guide enhances the ability of clinicians to make evidence-based decisions regarding off-label prescriptions.
  • It promotes rational drug therapy by providing access to relevant scientific literature.